CY1118151T1 - Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη - Google Patents
Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινηInfo
- Publication number
- CY1118151T1 CY1118151T1 CY20161100934T CY161100934T CY1118151T1 CY 1118151 T1 CY1118151 T1 CY 1118151T1 CY 20161100934 T CY20161100934 T CY 20161100934T CY 161100934 T CY161100934 T CY 161100934T CY 1118151 T1 CY1118151 T1 CY 1118151T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amyloidoidism
- inhibitor
- new transmission
- comt
- transmission treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
| EP12778323.1A EP2770988B1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118151T1 true CY1118151T1 (el) | 2017-06-28 |
Family
ID=47076222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100934T CY1118151T1 (el) | 2011-10-24 | 2016-09-20 | Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (enExample) |
| EP (1) | EP2770988B1 (enExample) |
| JP (1) | JP6068484B2 (enExample) |
| KR (1) | KR102017354B1 (enExample) |
| CN (1) | CN103889407B (enExample) |
| AU (2) | AU2012327275B2 (enExample) |
| BR (1) | BR112014009322B1 (enExample) |
| CA (1) | CA2852808C (enExample) |
| CL (1) | CL2014000893A1 (enExample) |
| CY (1) | CY1118151T1 (enExample) |
| ES (1) | ES2593038T3 (enExample) |
| IL (1) | IL231907B (enExample) |
| MX (2) | MX385516B (enExample) |
| PL (1) | PL2770988T3 (enExample) |
| PT (1) | PT2770988T (enExample) |
| RU (2) | RU2747536C2 (enExample) |
| SG (2) | SG10201609933WA (enExample) |
| WO (1) | WO2013060668A1 (enExample) |
| ZA (1) | ZA201402546B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
| KR102410072B1 (ko) * | 2014-08-29 | 2022-06-20 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법 |
| EP3275433A1 (en) | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| AU2019236469A1 (en) * | 2018-03-12 | 2020-10-08 | Corino Therapeutics, Inc. | Combination therapy for TTR amyloidosis |
| MX2021014682A (es) * | 2019-05-31 | 2022-04-06 | Plex Pharmaceuticals Inc | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. |
| WO2022104383A1 (en) * | 2020-11-13 | 2022-05-19 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating conditions of the eye |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
| EP4601624A2 (en) * | 2022-10-10 | 2025-08-20 | Corino Therapeutics, Inc. | Modified release tolcapone formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| WO1998027972A2 (en) | 1996-12-23 | 1998-07-02 | Texas A & M University | Anti-amyloidogenic agents |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| PT1372682E (pt) | 2001-03-15 | 2012-08-03 | Proteotech Inc | Catequinas para o tratamento de fibrilogénese em doença de alzheimer, doença de parkinson, amiloidose αa sistémica e outras perturbações amiloides |
| CN1688299A (zh) | 2002-01-29 | 2005-10-26 | 普罗特米克斯公司 | 抑制细胞毒性蛋白构象异构体 |
| US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| WO2005112913A1 (en) * | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
| ES2339790T3 (es) | 2004-08-30 | 2010-05-25 | Seo Hong Yoo | Efecto neuroprotector de udca solubilizado en modelo isquemico focal. |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
-
2012
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 MX MX2017006182A patent/MX385516B/es unknown
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh not_active Expired - Fee Related
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en not_active Ceased
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active Active
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en not_active Ceased
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en not_active Ceased
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1121379T1 (el) | Πολυθεραπεια για την ισχαιμια | |
| CY1122671T1 (el) | Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CY1120506T1 (el) | Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων | |
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CY1120374T1 (el) | Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια | |
| CR9882A (es) | Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2019010422A (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. | |
| CR20150571A (es) | Compuestos y composiciones terapéuticos | |
| CL2015002807A1 (es) | Terapia de combinación | |
| MX2020003174A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
| MX373925B (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| CL2015002534A1 (es) | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
| NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa |